Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
Date:8/5/2011

ated in the ongoing extension portion of Study 203.
  • Results from the completed 28-day main portion of the study showing, at the highest lesinurad dose tested, the number of patients taking the combination who achieved the target sUA level of below 6 mg/dL was more than three times the number of patients who achieved the target on allopurinol alone. This translated into an overall response rate of 87 percent using a "last observation carried forward", or LOCF, analysis. The combination of lesinurad and allopurinol was generally well tolerated in the 28-day main portion of Study 203.
  • Results from a completed preclinical study showing that lesinurad is an active inhibitor of the OAT4 transporter, a uric acid transporter in the kidney believed to be responsible for the hyperuricemia caused by the anti-hypertensive diuretic agent, hydrochlorothiazide.  As hypertension is a common co-morbid condition in gout patients, this secondary lesinurad activity may benefit gout patients taking this common treatment for hypertension. Consistent with these preclinical results, a high level of response was observed with lesinurad in the subset of patients receiving thiazide diuretics in Study 203.
  • In June 2011, we presented data from a completed, multi-center, Phase 1, monotherapy, dose-escalation study of BAY-86-9766 (RDEA119) in advanced cancer patients at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.  BAY 86-9766 (RDEA119) is a potent and highly selective inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer Healthcare.
  • We are currently preparing for the commencement of Phase 3 studies of lesinurad which will focus on patients who do not reach target serum uric acid levels with, or are intolerant to, the current standard of care, allopurinol.  In anticipation of these studies, we recently initiated two observational studies i
    '/>"/>

  • SOURCE Ardea Biosciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Ardea Biosciences to Present at Upcoming Investor Conferences
    2. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
    3. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
    4. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
    5. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
    6. Ardea Biosciences Prices Public Offering of Common Stock
    7. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
    8. Ardea Biosciences to Present at Two Upcoming Investor Conferences
    9. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    10. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    11. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... MA (PRWEB) December 23, 2014 Earlier ... Dr. James L. Sherley, director of the Adult Stem ... on an often overlooked and under appreciated unique property ... Self-Renewal by Distributed Stem Cells: Misunderstood in the Past, ... message to congress participants. He gave the address ...
    (Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ... the housing market remaining soft. , This solid economic news ...
    (Date:12/24/2014)... The report expects global cell isolation and expansion ... provides a carefully analyzed data about the vital drivers, ... , Full Copy of Report @ http://bit.ly/1yUxy0T ... cell expansion will keep witnessing growth at an impressive ... be driven by rapid technological advancements, government funding and ...
    (Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
    Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5
    ... Inc., a division of GE Industrial Systems, announced ... a Green Bay manufacturing software development company. , ... Execution Systems (MES) technology for the manufacturing of ... as well as for pulp and paper products. ...
    ... to fighting breast cancer, and GE Medical Systems, headquartered ... AD and Second Look Digital are computer-aided detection (CAD) ... digital mammography system. CADx Systems, Inc. developed the Second ... the review of breast exams. , ,GE is ...
    ... until he gets to the better drugs, faster part of ... behind the Madison-based companys products is likely to hit the ... age when diseases and treatments become as common in conversation ... and a half-year-old company that Vodenlich joined as president earlier ...
    Cached Biology Technology:Green Bay Software Company Purchased by GE 2New Technology in Fight against Breast Cancer 2Chipping Away at Drug Development 2Chipping Away at Drug Development 3
    (Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal ... that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four ... has served as a meeting place for peoples ... and the ongoing mixing of peoples with African, European, ...
    (Date:12/17/2014)... 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... technology than the iPhone 5S, Samsung introduces for ... product. The Galaxy S5 home button ...
    (Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB ... Good Clinical Practices (GCP) audit to confirm its ... (FDA) regulations. This accomplishment enables HITLAB to conduct ... utilizing the highest principles for patient safety and ... improve global healthcare access, quality, and delivery with ...
    Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
    ... the U.S. Department of Energy,s Brookhaven National Laboratory have ... against human adenovirus, a cause of ailments ranging from ... published in FEBS Letters , a journal of ... researchers sifted through thousands of compounds to determine which ...
    ... from Uppsala University, Sweden, show that the key to ... and Creutzfeldt-Jakob disease may lie in the ribosome, the ... recently published in the Journal of Biological Chemistry ... by misfolding of prion proteins. Examples of prion diseases ...
    ... that has sickened thousands in Haiti came from a single ... the past three years as some have thought, according to ... open-access journal of the American Society for Microbiology. ... findings that indicate Vibrio cholerae bacteria were introduced ...
    Cached Biology News:Scientists identify promising antiviral compounds 2Scientists identify promising antiviral compounds 3The ribosome -- a new target for antiprion medicines 2Genomes of cholera bacteria from Haiti confirm epidemic originated from single source 2Genomes of cholera bacteria from Haiti confirm epidemic originated from single source 3
    MAGP-2 (C-19)...
    Laminin gamma-2 (G-16)...
    ... Proliferation Kit, For 100 slides. Immunocytochemistry.Sample ... in vitro tissue labeling.Recommended cell number: ... (labeling 1-2 hours).Store at 2-8 C ... Category: Drug Screening & Cellular Assays, ...
    Dysadherin 2 (L-15)...
    Biology Products: